secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0000950170-22-002526
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX reports Q4 rev $19.7M, cash $305.2M; CX-2029 18.8% ORR, CX-904 IND allowed
--------------------------------------------------------------------------------

- Cash and equivalents $305.2M at Dec 31, 2021 vs $316.1M at Dec 31, 2020.
- Q4 2021 revenue $19.7M (up from $16.4M in Q4 2020); FY 2021 revenue $69.6M (down from $100.4M).
- CX-2029 Phase 2 in sqNSCLC: 18.8% objective response rate, 87.5% disease control rate; safety consistent.
- CX-904 (EGFRxCD3 TCB) IND allowed; Phase 1 in advanced solid tumors to start H1 2022.
- Praluzatamab ravtansine Phase 2 in breast cancer: initial data for Arms A & B expected H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017022002526/0000950170-22-002526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017022002526/ctmx-20220301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer